MVA-M1+NP vaccine candidate consists of MVA, a replication-deficient pox viral vector that has been safely tested in thousands of patients, to generate a strong immune reaction against Matrix 1 (M1) and Nucleoprotein (NP) influenza antigens.
MVA-M1+NP vaccine candidate is indicated to prevent a pandemic and seasonal influenza by eliciting broader and more durable immune protection against all “A strains” of the virus: including swine flu, avian (bird) flu, and human flu.
MVA-M1+NP is administered as an intramuscular injection as an adjunct to a standard quadrivalent influenza vaccine.
The antigens are highly conserved between influenza A viral subtypes and their intramuscular delivery in Vaccitech’s MVA vector construct induces a potent cell-mediated immune response intended to reduce the likelihood of developing clinical illness from influenza.
Clinical Trial NCT03880474: Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
- This is a Phase 2b, multicentre, randomized, single-blind study in up to 6000 adults to compare the efficacy, safety, and immunogenicity of MVA-NP+M1 when given as an adjunct to a standard, licensed adult dose of QIV.
- The study will be conducted on an outpatient basis and will run over two consecutive influenza seasons. It is aimed to recruit 2200 participants in Season 1 and 2800-3800 participants in Season 2.
Clinical Trial NCT03883113: Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
- A Phase 2, single-center, randomized, double-blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.